The global antibody drug conjugate (ADC) market size was valued at USD 13.51 billion in 2025 and is predicted to hit around ...

GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an ...

See more on Vaxcyte's (PCVX) and VAX-31’s broad pneumococcal vaccine pipeline, strong cash runway, and key 2026–2027 trial ...

Transcenta Holding-B (06628.HK) announced that it presented preclinical data at the 2026 AACR Annual Meeting highlighting its ...

Discover the emerging class of degrader-antibody conjugates – a modality that is drawing increasing interest from biotech ...

Peptide Drug Conjugates (PDCs) present major growth opportunities in oncology and beyond, triggered by innovations in peptide chemistry, enhanced targeting, and reduced systemic toxicity. With a ...

Meanwhile, peroxisome proliferation-activated receptors (PPARs) are obesity drug targets in their own right: activating them can reduce inflammation and restore insulin sensitivity. But molecules that ...

Researchers tested the peptide BLMP6 in breast cancer models. The peptide demonstrated selective binding to metastatic cells ...

Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced ...